Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Cytopenia 1

Interventions

Cyclophosphamide 94fludarabine phosphate 87Busulfan 64Cyclosporine 57Epoetin Alfa 55Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53fludarabine 45Antilymphocyte Serum 43Filgrastim 41Cytarabine 41Melphalan 40Tacrolimus 39Darbepoetin alfa 39Methotrexate 34Radiotherapy 33Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23apixaban 22Methylprednisolone 22Rivaroxaban 21Etoposide 21Thiotepa 17Dalteparin 17eltrombopag 16ferric carboxymaltose 14epoetin beta 14Daunorubicin 14Azacitidine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IDO-1 inhibitor LY3381916 × Classical hematology × Clear all
NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
15 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡